Gilead Sciences (GILD) Change in Receivables (2009 - 2026)

Gilead Sciences has reported Change in Receivables for 18 years, with the latest figure at -$134.0 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 69.62% year-over-year to -$134.0 million; the trailing twelve-month figure through Mar 2026 stood at $312.0 million (up 209.86% YoY), and the FY2025 full-year result was $367.0 million, up 364.03% from the prior year.
• Change in Receivables for Q1 2026 stood at -$134.0 million, up from -$179.0 million in the prior quarter.
• The five-year high for Change in Receivables was $612.0 million in Q3 2023, with the low at -$699.0 million in Q1 2022.
• Historically, Change in Receivables has averaged $20.2 million across 5 years, with a median of $29.0 million in 2024.
• The largest YoY upside for Change in Receivables was 906.9% in 2025 against a maximum downside of 219.7% in 2025.
• Gilead Sciences' Change in Receivables stood at $281.0 million in 2022, then plunged by 178.29% to -$220.0 million in 2023, then surged by 67.27% to -$72.0 million in 2024, then plunged by 148.61% to -$179.0 million in 2025, then rose by 25.14% to -$134.0 million in 2026.
• The last three Change in Receivables figures came in at -$134.0 million (Q1 2026), -$179.0 million (Q4 2025), and $333.0 million (Q3 2025), per Business Quant data.